Baseline Laboratory Test Abnormalities are Common in Early Arthritis but Rarely Contraindicate Methotrexate: Study of Three Cohorts (ESPOIR, VErA, and Brittany)

Seminars in Arthritis and Rheumatism

Volumn 42, Issue 5, 2013, Pages 474-481

  Le Boëdec, Marion ^a   Marhadour, Thierry ^a   Devauchelle Pensec, Valérie ^a   Jousse Joulin, Sandrine ^a   Binard, Aymeric ^a   Fautrel, Bruno ^b   Marc Flipo, René ^c   Le Loët, Xavier ^d   François Ménard, Jean ^e   Saraux, Alain ^a  

^a UNIVERSITÉ DE BRETAGNE OCCIDENTALE   (France)

^b PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^c LILLE UNIVERSITY HOSPITAL   (France)

^d UNIVERSITÉ DE ROUEN   (France)

^e ROUEN UNIVERSITY HOSPITAL   (France)

Author keywords

Anemia; Cytolysis; Methotrexate; Recent onset arthritis; Renal failure; Rheumatoid arthritis

Indexed keywords

ALANINE AMINOTRANSFERASE; ALBUMIN; ALKALINE PHOSPHATASE; ASPARTATE AMINOTRANSFERASE; BILIRUBIN; C REACTIVE PROTEIN; CREATININE; DISEASE MODIFYING ANTIRHEUMATIC DRUG; GAMMA GLUTAMYLTRANSFERASE; GLUCOCORTICOID; HEMOGLOBIN; METHOTREXATE;

ADULT; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANEMIA; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BLOOD CELL COUNT; COHORT ANALYSIS; CREATININE CLEARANCE; DISEASE SEVERITY; DRUG CONTRAINDICATION; ERYTHROCYTE SEDIMENTATION RATE; FEMALE; GLOMERULUS FILTRATION RATE; HUMAN; INFLAMMATION; KIDNEY DYSFUNCTION; LABORATORY TEST; LEUKOPENIA; LIVER DYSFUNCTION; MAJOR CLINICAL STUDY; MALE; MEDICAL DECISION MAKING; PREVALENCE; PRIORITY JOURNAL; RHEUMATOID ARTHRITIS; THROMBOCYTOPENIA;

ALANINE TRANSAMINASE; ANEMIA; ANTIRHEUMATIC AGENTS; ARTHRITIS; ASPARTATE AMINOTRANSFERASES; COHORT STUDIES; DIAGNOSTIC TESTS, ROUTINE; EARLY DIAGNOSIS; FEMALE; HUMANS; LEUKOPENIA; LIVER DISEASES; LIVER FUNCTION TESTS; MALE; METHOTREXATE; RENAL INSUFFICIENCY; SYSTEMIC INFLAMMATORY RESPONSE SYNDROME; THROMBOCYTOPENIA;

EID: 84876973836     PISSN: 00490172     EISSN: 1532866X     Source Type: Journal    
DOI: 10.1016/j.semarthrit.2012.08.001     Document Type: Article

References (39)

1. Van Dongen H., Van Aken J., Lard L.R., Visser K., Ronday H.K., Hulsmans H.M., et al. Efficacy of methotrexate treatment in patients with probable rheumatoid arthritis: a double-blind, randomized, placebo-controlled trial. Arthritis Rheum 2007, 56:1424-1432.
2. Williams H.J., Willkens R.F., Samuelson C.O., Alarcón G.S., Guttadauria M., Yarboro C., et al. Comparison of low-dose oral pulse methotrexate and placebo in the treatment of rheumatoid arthritis. A controlled clinical trial. Clin Exp Rheum 2010, 28:73-78.
3. Weinblatt M.E., Coblyn J.S., Fox D.A., Fraser P.A., Holdsworth D.E., Glass D.N., et al. Efficacy of low-dose methotrexate in rheumatoid arthritis. N Engl J Med 1985, 28(312):818-822.
4. Groff G.D., Shenberger K.N., Wilke W.S., Taylor T.H. Low dose oral methotrexate in rheumatoid arthritis: an uncontrolled trial and review of the literature. Semin Arthritis Rheum 1983, 12:333-347. [Review].
5. Alarcón G.S. Methotrexate use in rheumatoid arthritis. A Clinician's perspective. Immunopharmacology 2000, (47):259-271. [Review].
6. Vidal Dictionary. Paris. Vidal SA edition; 2010.
7. http://www.has-sante.fr/portail/upload/docs/application/pdf/synthese_des_resumes_traitements_de_fond.pdf.
8. Pavy S., Constantin A., Pham T., Gossec L., Maillefert J.F., Cantagrel A., et al. Methotrexate therapy for rheumatoid arthritis: clinical practice guidelines based on published evidence and expert opinion. Joint Bone Spine 2006, 73:388-395.
9. Visser K., Katchamart W., Loza E., Martinez-Lopez J.A., Salliot C., Trudeau J., et al. Multinational evidence-based recommendations for the use of methotrexate in rheumatic disorders with a focus on rheumatoid arthritis: integrating systematic literature research and expert opinion of a broad international panel of rheumatologists in the 3E Initiative. Ann Rheum Dis 2009, 68:1086-1093.
10. Smolen J.S., van der Heijde D. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs. Ann Rheum Dis 2010, 69:964-975.
11. Gaujoux-Viala C., Smolen J.S., Landewé R., Dougados M., Kvien T.K., Mola E.M., et al. Current evidence for the management of rheumatoid arthritis with synthetic disease-modifying antirheumatic drugs: a systematic literature review informing the EULAR recommendations for the management of rheumatoid arthritis. Ann Rheum Dis 2010, 69:1004-1009.
12. Saag K.G., Teng G.G., Patkar N.M., Anuntiyo J., Finney C., Curtis J.R., et al. American College of Rheumatology 2008 recommendations for the use of nonbiologic and biologic disease-modifying antirheumatic drugs in rheumatoid arthritis. Arthritis Rheum 2008, 59:762-784.
13. Saraux A., Fautrel B., Maillefert J.F., Flipo R.M., Kaye O., Lafforgue P., et al. Club rheumatism and inflammation. Laboratory and imaging studies used by French rheumatologists to evaluate patients with early arthritis. J Rheumatol 2006, 33:897-902.
14. Combe B., Benessiano J., Berenbaum F., Cantagrel A., Daurès J.P., Dougados M., et al. The ESPOIR cohort: a ten-year follow-up of early arthritis in France: methodology and baseline characteristics of the 813 included patients. Joint Bone Spine 2007, 74:440-445.
15. Le Loët X., Brazier M., Mejjad O., Boumier P., Daragon A., Gayet A., et al. Serum IgA rheumatoid factor and pyridinoline in very early arthritis as predictors of erosion(s) at two years: a simple model of prediction from a conservatively treated community-based inception cohort. Arthritis Care Res (Hoboken) 2010, 62:1739-1747.
16. Saraux A., Berthelot J.M., Chalès G., Le Henaff C., Thorel J.B., Hoang S., et al. Ability of the American College of Rheumatology 1987 criteria to predict rheumatoid arthritis in patients with early arthritis and classification of these patients two years later. Arthritis Rheum 2001, 44:2485-2491.
17. http://whqlibdoc.who.int/publications/2008/9789241596657_eng.pdf.
18. Critical reading of the CBC: Threshold values to be recognized as probably the major pathological and nonpathological variations. Anaes recommendations; 1999.
19. Cockcroft D.W., Gault M.H. Prediction of creatinine clearance from serum creatinine. Nephron 1976, 16:31-41.
20. K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Am J Kidney Dis 2002, 39(Suppl. 1):S1-S266. National Kidney Foundation.
21. Diagnosis of chronic renal failure in adults. Anaes recommendations, 2003.
22. Kent P.D., Luthra H.S., Michet C. Risk factors for methotrexate-induced abnormal laboratory monitoring results in patients with rheumatoid arthritis. J Rheumatol 2004, 31:1727-1731.
23. Walker A.M., Funch D., Dreyer N.A., Tolman K.G., Kremer J.M., Alarcon G.S., et al. Determinants of serious liver disease among patients receiving low-dose methotrexate for rheumatoid arthritis. Arthritis Rheum 1993, 36:329-335.
24. The effect of age and renal function on the efficacy and toxicity of methotrexate in rheumatoid arthritis. J Rheumatol 1995, 22:218-223. Rheumatoid Arthritis Clinical Trial Archive Group.
25. Alarcon G.S., Kremer J.M., Macaluso M., Weinblatt M.E., Cannon G.W., Palmer W.R., et al. Risk factors for methotrexate-induced lung injury in patients with rheumatoid arthritis. A multicenter, case-control study. Methotrexate-Lung Study Group. Ann Intern Med 1997, 127:356-364.
26. Anders H.J., Rihl M., Vielhauer V., Schattenkirchner M. Assessment of renal function in rheumatoid arthritis: validity of a new prediction method. J Clin Rheumatol 2002, 8:130-133.
27. Karie S., Gandjbakhch F., Janus N., Launay-Vacher V., Rozenberg S., Mai Ba CU, et al. Kidney disease in RA patients: prevalence and implication on RA-related drugs management: the MATRIX study. Rheumatology (Oxford) 2008, 47:350-354.
28. Izzedine H., Launay-Vacher V., Karie S., Caramella C., de Person F., Deray G. Is low-dose methotrexate nephrotoxic? Case report and review of the literature. Clin Nephrol 2005, 64:315-319.
29. Bressolle F., Bologna C., Kinowski J.M., Sany J., Combe B. Effects of moderate renal insufficiency on pharmacokinetics of methotrexate in rheumatoid arthritis patients. Ann Rheum Dis 1998, 57:110-113.
30. Boey O., Van Hooland S., Woestenburg A., Van der Niepen P., Verbeelen D. Methotrexate should not be used for patients with end-stage kidney disease. Acta Clin Belg 2006, 61:166-169.
31. Baer A.N., Dessypris E.N., Krantz S.B. The pathogenesis of anemia in rheumatoid arthritis: a clinical and laboratory analysis. Semin Arthritis Rheum 1990, 19:209-223.
32. Wolfe F., Michaud K. Anemia and renal function in patients with rheumatoid arthritis. J Rheumatol 2006, 33:1516-1522.
33. Bertin P., Carpentier N., Vergne P., Bonnet C., Bannwarth B., Dehais J., et al. Methotrexate and non-steroidal anti-inflammatory agent combination in rheumatoid arthritis. Therapie 1997, 52:133-137.
34. Pincus T., Furer V., Sokka T. Underestimation of the efficacy, effectiveness, tolerability, and safety of weekly low-dose methotrexate in information presented to physicians and patients. Clin Exp Rheumatol 2010, 28(5 Suppl. 61):S68-S79.
35. Mckendry R.J., Freeman C., Dale P. AST and/or ALT for methotrexate monitoring. Arthritis Rheum 1995, 38(Suppl. 9):680.
36. Visser K., van der Heijde D.M. Risk and management of liver toxicity during methotrexate treatment in rheumatoid and psoriatic arthritis: a systematic review of the literature. Clin Exp Rheumatol 2009, 27:1017-1025.
37. Guennoc X., Narbonne V., Jousse-Joulin S., Devauchelle-Pensec V., Dougados M., Daurès J.P., et al. Is screening for hepatitis B and hepatitis C useful in patients with recent-onset polyarthritis? The ESPOIR cohort study. J Rheumatol 2009, 36:1407-1413.
38. Varache S., Narbonne V., Jousse-Joulin S., Guennoc X., Dougados M., Daurès J.P., et al. Is routine viral screening useful in patients with recent-onset polyarthritis of a duration of at least 6 weeks? Results from a nationwide longitudinal prospective cohort study. Arthritis Care Res (Hoboken) 2011, 63:1565-1570.
39. Yazici Y., sokka T., Kautiainen H., Swearingen C., Kulman I., Pincus T. Long term safety of methotrexate in routine clinical care: discontinuation is unusual and rarely the result of laboratory abnormalities. Ann Rheum Dis 2005, 64:207-211.